- Home
- BCAL vs CRVS Comparison
BCAL vs CRVS Comparison
Compare BCAL & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCAL | CRVS |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 528.7M | 546.7M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | BCAL | CRVS |
|---|---|---|
| Price | $18.59 | $8.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $20.00 | $13.75 |
| AVG Volume (30 Days) | 223.4K | ★ 1.6M |
| Earning Date | 01-27-2026 | 11-04-2025 |
| Dividend Yield | ★ 2.16% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.92 | N/A |
| Revenue | ★ $187,714,000.00 | N/A |
| Revenue This Year | $72.83 | N/A |
| Revenue Next Year | $3.14 | N/A |
| P/E Ratio | $9.67 | ★ N/A |
| Revenue Growth | ★ 139.72 | N/A |
| 52 Week Low | $11.87 | $2.54 |
| 52 Week High | $20.47 | $9.60 |
Technical Indicators
Market Signals| Indicator | BCAL | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 44.87 | 58.46 |
| Support Level | $17.89 | $6.46 |
| Resistance Level | $18.99 | $7.18 |
| Average True Range (ATR) | 0.39 | 0.50 |
| MACD | -0.02 | 0.08 |
| Stochastic Oscillator | 50.80 | 93.26 |
Price Performance
Historical ComparisonAbout BCAL Southern California Bancorp
California BanCorp is a registered bank holding company headquartered in San Diego, California. The Bank offers a range of financial products and services to individuals, professionals, and small to medium-sized businesses through its 14 branch offices and four loan production offices serving Northern and Southern California. The Bank's solutions-driven, relationship-based approach to banking provides accessibility to decision-makers and enhances value through partnerships with its clients. The company has one operating segment: Commercial Banking.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).